 BMO Capital has initiated coverage on Centessa Pharmaceuticals plc NASDAQ: CNTA with a price target of 19 293 upside, and an Outperform rating. The analyst writes that ZF874 is a differentiated oral therapy as it addresses the root cause of AATD. 